Press release
Global Nonalcoholic Steatohepatitis Therapeutics Market
Transparency Market Research (TMR), a market intelligence company answers some of the chief questions that may prove helpful for companies already established in the Nonalcoholic Steatohepatitis market and also for emerging companies looking to penetrate this market.
Browse Market Research Report @http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html
Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly.
It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.
The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.
Fill the form to gain deeper insights on this market @http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691
Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.
The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.
Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Nonalcoholic Steatohepatitis Therapeutics Market here
News-ID: 480141 • Views: …
More Releases from TMR
Emerging Opportunities in Logistics Market with Current Trends Analysis
The global Logistics market is estimated to attain a valuation of US$ 15,273.21 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.5% during the forecast period, 2019-2027.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the…
Energy Measurement IC Market is expected to reach US$ 8.39 Bn by the end of 2031
According to a Transparency Market Research (TMR) research report, the global energy measurement ic market is likely to expand at a CAGR of 7.4% during the forecast period, 2022 to 2031. This suggests that the market is expected to reach US$ 8.39 Bn by the end of 2031.
The study on the energy measurement ic market adopts rigorous and systematic research approaches to understand the growth dynamic of the market. The…
STATCOM UPS Market to Register Double Digit Growth Rate of 16% CAGR by 2024
Over the last decade, rising number of industries and utilities are opting for static synchronous compensator or STATCOM UPS instead of static VAR compensator or SVC UPS. Low harmonic emission coupled with high speed of response is accentuating the expansion of India STATCOM UPS market now and in times to come. Playing a crucial role in voltage control and compensation of reactive power, STATCOM UPS is likely to keep its…
Thin Wafer Processing and Dicing Equipment Market US$692.5 mn by 2024 - TMR
Transparency Market Research (TMR) estimates that the global thin wafer processing and dicing equipment market has a highly consolidative landscape. Disco Corp. accounted for largest share of 56.4% in 2015 and likely to be dominant in the coming years. This is creating monopoly in the thin wafer processing and dicing equipment market in terms of competitive presence. The other key players such as EV Group, Plasma-Therm LLC, Lam Research Corp,…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
